Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | PAR 24 072

Opportunity Information: Apply for PAR 24 072

The Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required), PAR-24-072, is a National Institutes of Health (NIH) funding opportunity administered by the National Cancer Institute (NCI) to support investigator-initiated clinical trials focused on reducing the overall burden of cancer. The program is designed for trials that can meaningfully improve outcomes across the cancer continuum by advancing early detection, screening, prevention and interception strategies, healthcare delivery, quality of life, and survivorship. A central expectation is that funded studies will not only generate strong scientific evidence, but also have clear potential to influence real-world clinical practice and/or public health.

A key requirement is that applications must propose research that meets the NIH definition of a clinical trial and include the specific clinical trial information requested by the funding announcement, consistent with NIH policy (referenced as NOT-OD-15-015). In other words, this is not a mechanism for observational or non-trial research under the clinical trial umbrella; the funding opportunity is explicitly set up to receive and support genuine clinical trials, with trial-specific details and compliance elements built into the application.

At the same time, the scope is clearly limited in what it will not fund. This NOFO does not support clinical trials aimed at cancer diagnosis and/or oncologic therapy in patients. Applicants should interpret this as an exclusion of trials primarily evaluating therapeutic cancer treatments or diagnostic workups as part of managing patients with cancer. Instead, the emphasis is on prevention and control domains such as improving screening strategies, testing interventions that support prevention or interception before cancer develops or progresses, strengthening delivery of evidence-based care and supportive services, and improving survivorship and quality-of-life outcomes.

Programmatically, proposed projects should align with the mission areas and interests of the NCI Division of Cancer Prevention (DCP) and/or the NCI Division of Cancer Control and Population Sciences (DCCPS). That framing signals that the NCI is looking for trials grounded in prevention, population science, behavioral and implementation approaches, healthcare systems and delivery, survivorship, and related cancer control research, rather than treatment trials conducted in oncology therapeutic settings.

Eligibility is broad and includes many types of domestic and non-domestic organizations. Eligible applicants include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized governments); public housing authorities/Indian housing authorities; nonprofits (both with and without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses. The opportunity also explicitly highlights additional eligible applicants such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and foreign (non-U.S.) entities.

The funding instrument is an NIH grant using the R01 mechanism, and the opportunity is categorized as discretionary. It is associated with CFDA numbers 93.393 and 93.399. The original closing date listed is January 7, 2027. The provided listing does not specify an award ceiling or the expected number of awards, so applicants would typically need to consult the full NOFO and NIH budgeting guidance for details on allowable costs, project periods, and any program-specific budget expectations.

Overall, PAR-24-072 is best understood as an NCI R01 clinical trial funding pathway for research teams who are ready to run a well-defined clinical trial that targets cancer prevention or cancer control outcomes, produces actionable evidence, and fits squarely outside of oncology therapeutic and diagnostic trial territory.

• The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.399.
• This funding opportunity was created on 2023-12-15.
• Applicants must submit their applications by 2027-01-07.
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 24 072

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: